[go: up one dir, main page]

WO2002100343A3 - N-terminally truncated galectin-3 and antibodies for treating cancer - Google Patents

N-terminally truncated galectin-3 and antibodies for treating cancer Download PDF

Info

Publication number
WO2002100343A3
WO2002100343A3 PCT/US2002/018478 US0218478W WO02100343A3 WO 2002100343 A3 WO2002100343 A3 WO 2002100343A3 US 0218478 W US0218478 W US 0218478W WO 02100343 A3 WO02100343 A3 WO 02100343A3
Authority
WO
WIPO (PCT)
Prior art keywords
terminally truncated
pharmaceutically acceptable
effective amount
acceptable carrier
truncated galectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/018478
Other languages
French (fr)
Other versions
WO2002100343A2 (en
Inventor
Gary A Jarvis
Constance M John
Hakon Leffler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MANDALMED Inc
Original Assignee
MANDALMED Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MANDALMED Inc filed Critical MANDALMED Inc
Priority to EP02756157A priority Critical patent/EP1534317A4/en
Priority to CA002488850A priority patent/CA2488850A1/en
Priority to AU2002322066A priority patent/AU2002322066A1/en
Publication of WO2002100343A2 publication Critical patent/WO2002100343A2/en
Priority to US10/726,198 priority patent/US20050032673A1/en
Anticipated expiration legal-status Critical
Publication of WO2002100343A3 publication Critical patent/WO2002100343A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

There is provided a composition having an effective amount of N-terminally truncated galectin-3 in a pharmaceutically acceptable carrier or an effective amount of a nucleic acid sequence encoding N-terminally truncated galectin-3 in a pharmaceutically acceptable carrier. Also provided by the present invention is a method of treating cancer by administering to a patient in need of such treatment an effective amount of N-terminally truncated galectin-3 in a pharmaceutically acceptable carrier or an effective amount of a nucleic acid sequence encoding N-terminally truncated galectin-3 in a pharmaceutically acceptable carrier. The present invention also provides an antibody that specifically binds to carbohydrate ligands of galectin-3. Further, there is provided an anti-cancer treatment having an effective amount of N-terminally truncated galectin-3 and a pharmaceutically acceptable carrier or an effective amount of nucleic acid sequence encoding N-terminally truncated galectin-3 in a pharmaceutically acceptable carrier.
PCT/US2002/018478 2001-06-08 2002-06-10 N-terminally truncated galectin-3 and antibodies for treating cancer Ceased WO2002100343A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP02756157A EP1534317A4 (en) 2001-06-08 2002-06-10 N-terminally truncated galectin-3 and antibodies for treating cancer
CA002488850A CA2488850A1 (en) 2001-06-08 2002-06-10 Sustained release n-terminally truncated galectin-3 and antibodies to galectin-3 carbohydrate ligands for use in treating cancer
AU2002322066A AU2002322066A1 (en) 2001-06-08 2002-06-10 N-terminally truncated galectin-3 and antibodies for treating cancer
US10/726,198 US20050032673A1 (en) 2002-06-10 2003-12-02 Sustained release N-terminally truncated galectin-3 and antibodies to galectin-3 carbohydrate ligands for use in treating disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29697001P 2001-06-08 2001-06-08
US60/296,970 2001-06-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/726,198 Continuation-In-Part US20050032673A1 (en) 2002-06-10 2003-12-02 Sustained release N-terminally truncated galectin-3 and antibodies to galectin-3 carbohydrate ligands for use in treating disease

Publications (2)

Publication Number Publication Date
WO2002100343A2 WO2002100343A2 (en) 2002-12-19
WO2002100343A3 true WO2002100343A3 (en) 2005-03-17

Family

ID=23144316

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/018478 Ceased WO2002100343A2 (en) 2001-06-08 2002-06-10 N-terminally truncated galectin-3 and antibodies for treating cancer

Country Status (4)

Country Link
EP (1) EP1534317A4 (en)
AU (1) AU2002322066A1 (en)
CA (1) CA2488850A1 (en)
WO (1) WO2002100343A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835556B2 (en) 2002-12-31 2014-09-16 Nektar Therapeutics Hydrolytically stable maleimide-terminated polymers
US9381159B2 (en) 2011-12-05 2016-07-05 Tuo Jin Microspheres for controlled- or sustained-release delivery of therapeutics

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE444984T1 (en) 2002-12-31 2009-10-15 Nektar Therapeutics Al Corp HYDROLYSIS-STABLE POLYMERS CONTAINING MALEIMIDE END GROUPS
EP1617849B1 (en) 2003-04-07 2008-06-18 Prospect Therapeutics, Inc. Composition and uses of galectin antagonists
AU2009340423B2 (en) * 2008-10-29 2014-07-24 Bg Medicine, Inc. Galectin-3 immunoassay
EP2934552A4 (en) 2012-12-20 2016-07-27 Ford Henry Health System METHOD FOR TREATING DIASTOLIC HEART FAILURE BY INHIBITING GALECTIN-3
US12390486B2 (en) 2012-12-20 2025-08-19 Henry Ford Health System Method for treating diastolic heart failure by inhibiting galectin-3
US20150157691A1 (en) * 2013-12-05 2015-06-11 Texas Tech University System Galectin-3 to Treat Ovarian Cancer
EP3102247A4 (en) * 2014-02-03 2017-09-13 Texas Tech University System Galectin-3 inhibitor (gal-3m) is associated with additive anti-myeloma and anti-solid tumor effects, decreased osteoclastogenesis and organ protection when used in combination with proteasome inhibitors
SG10201902499VA (en) 2014-09-03 2019-04-29 Genesegues Inc Therapeutic nanoparticles and related compositions, methods and systems

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020019009A1 (en) * 1999-12-09 2002-02-14 Roggen Erwin Ludo High throughput screening (HTS) assays

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI865253L (en) * 1985-04-23 1986-12-22 Medical Biology Inst IDENTIFIERING AV IGE-BINDINGSPROTEIN MED HJAELP AV MOLEKYLKLONING.
AU2001243622A1 (en) * 2000-03-13 2001-09-24 La Jolla Institute For Allergy And Immunology Monocyte chemoattractant activity of galectin-3

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020019009A1 (en) * 1999-12-09 2002-02-14 Roggen Erwin Ludo High throughput screening (HTS) assays

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CLINICAL CANCER RESEARCH, vol. 9, June 2003 (2003-06-01), pages 2374 - 2383 *
DATABASE MEDLINE [online] CONSTANCE ET AL.: "Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer", XP002992511, accession no. dialog Database accession no. NLM12796408 *
GONG ET AL.: "The NH2 Terminus of Galectin-3 Governs Cellular Compartimentalization and Functions in Cancer cells", CANCER RESEARCH, vol. 59, 15 December 1999 (1999-12-15), pages 6239 - 6245, XP002984373 *
PELLETIER ET AL.: "Specific recognition and cleavage of galectin-3 by Leishmania major through spieces-specific polygalactose epitope", J. BIOL. CHEM., vol. 277, 17 May 2002 (2002-05-17), pages 17663 - 17670, XP002984372 *
See also references of EP1534317A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835556B2 (en) 2002-12-31 2014-09-16 Nektar Therapeutics Hydrolytically stable maleimide-terminated polymers
US9381159B2 (en) 2011-12-05 2016-07-05 Tuo Jin Microspheres for controlled- or sustained-release delivery of therapeutics

Also Published As

Publication number Publication date
EP1534317A2 (en) 2005-06-01
CA2488850A1 (en) 2002-12-19
AU2002322066A1 (en) 2002-12-23
WO2002100343A2 (en) 2002-12-19
EP1534317A4 (en) 2005-10-12

Similar Documents

Publication Publication Date Title
WO2002083171A3 (en) Cancer treatment by using fap-alpha specific antibodies
AU3651802A (en) Recombinant anti-cd30 antibodies and uses thereof
WO2003054216A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2005000246A3 (en) Methods and compositions for treating rheumatoid arthritis
IL140138A (en) Specific antibodies of tie-2 ligands
WO2004018000A3 (en) Compositions and methods for treating cancer using maytansinoid cd44 antibody immonoconjugates and chemotherapeutic agents
WO2002097033A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2004068931A3 (en) Amphiregulin antibodies and their use to treat cancer and psoriasis
WO2003059951A8 (en) Novel anti-igf-ir antibodies and uses thereof
WO2003043583A3 (en) Treatment of immunological disorders using anti-cd30 antibodies
WO2003016467A3 (en) Use of antibodies having high affinity for soluble ass to treat conditions and diseases related to ass
WO2002100343A3 (en) N-terminally truncated galectin-3 and antibodies for treating cancer
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
WO2002077172A3 (en) Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-il8 and anti-muc18 in diverse types of tumors
WO2003017939A3 (en) Piperazinone compounds as anti-tumor and anti-cancer agents and methods of treatment
SI1684770T1 (en) Oligo-beta-(1,3)-glucan and monoclonal antibodies against cancer
PL330705A1 (en) Tie-2 receptor ligands (ligand-3 tie; ligand-4 tie) and their application
WO2005016236A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2003009870A1 (en) Remedies for mammary cancer
WO2004067564B1 (en) Compositions against cancer antigen liv-1 and uses thereof
AU2003241024A1 (en) Methods and compositions for radioimmunotherapy of brain and cns tumors
SG148190A1 (en) Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer
WO2002079377A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2003042367A3 (en) Antibodies that immunospecifically bind to trail receptors
WO2003097082A3 (en) Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002756157

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2488850

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2002756157

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP